Salute e Benessere

BTL's EMSCULPT NEO Used in Astronaut Training in Hungary for International Space…

"Studies show astronauts lose up to 30% of muscle mass in orbit, depending on the duration of the mission. EMSCULPT NEO has been an essential part of physical conditioning and rehabilitation, helping us maximize both muscle performance and recovery,"said Dr. Nóra Sydó, a cardiologist and sports medicine specialist from Semmelweis University,Budapest, who led the astronaut training team. EMSCULPT NEO was part of a comprehensive conditioning protocol designed to improve endurance,...
PR Newswire
20/10/2025

Faucet Market Growing at 5.93% CAGR to USD 31Bn by 2030, Amid Rising Smart…

Rising Focus on Water-Efficient Standards Rising Focus on Water-Efficient Standards Governments are tightening water-efficiency norms, pushing faucet makers to innovate and meet new certification standards. Eco-labels and rebate programs are shaping consumer preferences, turning compliance efforts into a market advantage for sustainable brands. Rising Urban Housing Upgrades Rapid urban growth in developing regions is driving steady demand for modern plumbing and stylish faucet...
PR Newswire
20/10/2025

Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating…

ATG-022 and CLINCH Study Overview ATG-022 and CLINCH Study Overview Key Results Presented Conclusions and Outlook Forward-looking statementsPlease refer:https://www.antengene.com/newsinfo/442 For more information, please contact: Investor Contacts:Donald LungE-mail:donald.lung@antengene.com BD Contacts:Ariel GuoE-mail:ariel.guo@antengene.com Logo -https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg View original content:...
PR Newswire
20/10/2025

Sobi Q3 2025 report: Accelerated growth and portfolio momentum

Outlook 2025 - updated Outlook 2025 - updated Financial summary * The strategic portfolio includes Sobi's medicines Altuvoct, Aspaveli/Empaveli, Doptelet, Gamifant, Vonjo and Zynlonta, and royalty on Sanofi's sales of Altuviiio and Beyfortus. Investors, analysts, and the media are invited to a conference call on the same day at13:00 CEST,12:00 BST, and07:00 EDT. The call will include a presentation of the results and a Q&A session. The presentation can be followed...
PR Newswire
20/10/2025

Coloplast A/S - FY 2024/25 Earnings Release - Invitation for conference call on…

Tuesday, 4 November 2025 at 11:00 - 12:00am CETIn connection with the publication of Coloplast’s interim financial results for FY 2024/25, to be released same day around 07.00am CET, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast’s website approximately 1 hour before the conference call. The webcast of the conference call will be available during and after the...
Nasdaq GlobeNewswire
20/10/2025

ESMO releases first-ever guidance for safe use of AI Language Models in cancer…

"Innovation must serve oncologists and, ultimately, patients, not confuse or mislead them," said Fabrice André, ESMO President. "With ELCAP, we offer a practical guide for using AI responsibly in oncology, one that protects data, ensures clinical oversight, and supports informed decision-making." "Innovation must serve oncologists and, ultimately, patients, not confuse or mislead them," said Fabrice André, ESMO President. "With ELCAP, we offer a practical guide…
PR Newswire
20/10/2025

Live from ESMO | Hengrui Debuts Exhibition Booth with Landmark Data Showcasing…

In parallel, Hengrui scheduled a series of academic events, fostering in-depth dialogue with leading global experts and clinical researchers on cutting-edge topics in oncology. These initiatives established a dynamic platform for international academic exchange and infused Chinese innovation into the global landscape of cancer diagnosis and treatment – marking a new chapter in Hengrui's journey of international scientific engagement. In parallel, Hengrui scheduled a series of academic events,...
PR Newswire
20/10/2025

Outfit7: Teeth and Treats Take Over My Talking Tom Friends in Halloween Update

Halloween Everywhere Halloween Everywhere From the moment players enter the game, the Halloween spirit is everywhere. Neighborhoods and character homes are festively decorated, complete with subtle spooky touches in every room. The fridge is stocked with seasonal favorites like "Witch Hat Pancakes" and "Zombie Sandwiches," while six special Halloween outfits - Werewolf, Mummy, Vampire, Pumpkin, Alien, and Bruja - add extra frightful flair (three of them even come with special…
PR Newswire
20/10/2025

Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential…

ESMO: AlphaMedix TMphase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumorsNew AlphaMedix data showed sustained and clinically meaningful responses across both RLT-naïve and RLT-exposed patients with unresectable or metastatic GEP-NETs First phase 2 study to evaluate TAT with lead-212 supporting its potential to address high unmet medical needs in difficult-to-treat, rare cancersPhase 2 study met all primary...
Nasdaq GlobeNewswire
20/10/2025

Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential…

ESMO: AlphaMedix TMphase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors New AlphaMedix data showed sustained and clinically meaningful responses across both RLT-naïve and RLT-exposed patients with unresectable or metastatic GEP-NETs First phase 2 study to evaluate TAT with lead-212 supporting its potential to address high unmet medical needs in difficult-to-treat, rare cancersPhase 2 study met...
Nasdaq GlobeNewswire
20/10/2025

Accord Plasma B.V. Expands Global Plasma Therapy Capabilities with Acquisition…

Prothya Biosolutions is one of Europe's leading plasma fractionators, operating major facilities in Amsterdam and Brussels, along with plasma collection centres across Hungary. The company employs approximately 1,200 skilled professionals. Prothya Biosolutions is one ofEurope'sleading plasma fractionators, operating major facilities inAmsterdamandBrussels, along with plasma collection centres acrossHungary. The company employs approximately 1,200 skilled professionals. ...
PR Newswire
20/10/2025

Roche’s Tecentriq showed significant overall and disease-free survival benefits…

Tecentriq reduced the risk of death by 41% and the risk of disease recurrence or death by 36% compared with placebo 1 IMvigor011 is the first global phase III study to read out pioneering a ctDNA- guided approach to post-surgery treatment in muscle-invasive bladder cancerData being presented as part of the Presidential Symposium at the ESMO Congress 2025 Basel, 20 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the phase III IMvigor011...
Nasdaq GlobeNewswire
20/10/2025

FDA approves Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis

FDA approval based on superiority of Gazyva/Gazyvaro over standard therapy alone, as shown in phase II NOBILITY and phase III REGENCY data 1,2 Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study 2 Lupus nephritis affects more than 1.7 million people worldwide, predominantly women of colour and childbearing age, with up to one-third of patients progressing to end-stage kidney...
Nasdaq GlobeNewswire
20/10/2025

Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior…

Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose Compared to standard-dose influenza vaccines, Efluelda/Fluzone High-Dose demonstrated a reduction in laboratory-confirmed influenza hospitalizations by an additional 31.9% (95% CI, 19.7 to 42.2; p<0.001) in adults 65 years and overResults come from FLUNITY-HD, the largest influenza vaccine effectiveness study of individually randomized older adults,...
Nasdaq GlobeNewswire
20/10/2025

Sobi announces revised full year outlook and advances publication of the Q3 2025…

Group Outlook 2025 Group Outlook 2025 At the publication of the Q4 2024 report on5 February 2025Sobi stated the outlook for the FY 2025 to be: Revenue was anticipated to grow by a high single digit percentage at CER and adjusted EBITA margin was anticipated to be in the mid-30s per cent of revenue. Sobi has now upgraded its full-year revenue outlook based on year-to-date performance and accelerated momentum in Q3. Group revenue grew 15 per cent at CER year-to-date and 21 per cent at...
PR Newswire
19/10/2025

PSMAddition data show Novartis Pluvicto™ delays progression to end-stage…

Pluvicto TMplus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR 0.72) versus SoC alone, with positive trend in OS (HR 0.84) in PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC) 1 Most patients with mHSPC progress to metastatic castration-resistant prostate cancer, underscoring urgent need for new therapies that can reduce risk of progression in earlier disease settings 2 ,3 The safety profile and tolerability of...
Nasdaq GlobeNewswire
19/10/2025

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan…

Media Release COPENHAGEN, Denmark; October 18, 2025 Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S®) 100 mg/m2 demonstrated 50% confirmed objective response rate (ORR), including two complete responses (CR), regardless of FRα expressionA Phase 3 trial in endometrial cancer is underwayU.S. FDA recently granted Breakthrough Therapy Designation to Rina-S for advanced endometrial cancer Genmab A/S (Nasdaq:GMAB) a...
Nasdaq GlobeNewswire
18/10/2025

Roche’s phase III evERA data showed giredestrant significantly improved…

Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT andESR1 -mutated populations, respectively, in a post-CDK inhibitor setting, compared with standard-of-care endocrine therapy plus everolimus 1 The giredestrant combination was well tolerated; no new safety signals were observed including no photopsia 1Overall survival data were immature, but a clear positive trend was seen in both the ITT andESR1 -mutated populations 1 If...
Nasdaq GlobeNewswire
18/10/2025

FDA approves Novo Nordisk's oral semaglutide for cardiovascular (CV) risk…

This new indication makes Rybelsus® the only oral GLP-1 medicine approved to reduce the risk of MACE in adults with type 2 diabetes who are at high risk for these events. It serves for both primary prevention (reducing the risk of major adverse cardiovascular events by preventing or managing risk factors in adults who are at high risk for these events) and secondary prevention (reducing the risk of another event in people who have had a serious CV event). This new indication makes Rybelsus ®...
PR Newswire
17/10/2025

Roche presents new phase III pivotal data for vamikibart in uveitic macular…

Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving UME and may offer a potential new treatment option for patientsVision improvements were seen in both pivotal studies, achieving statistical significance in MEERKAT and nominal significance in SANDCATThe MEERKAT and SANDCAT trials are ongoing and the data will be discussed with health authorities globallyBasel, 17 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today results...
Nasdaq GlobeNewswire
17/10/2025

Fagron’s share buy-back program: Weekly update

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 17 October 2025 – 6PM CET Fagron’s share buy-back program: Weekly update In the period from 16 October 2025 through 17 October 2025, Fagron purchased 20,000 of its owns shares at an average price of € 20.609 per share corresponding to a total amount of € 412,180.00. These purchases are part of the share buy-back program of up to 200,000 Fagron shares to fulfill Fagron’s obligations under its long-term incentive scheme,...
Nasdaq GlobeNewswire
17/10/2025

Oxurion Receives Amended Transparency Notifications from Atlas Special…

Oxurion Receives Amended Transparency Notifications from Atlas Special Opportunities II LLC Leuven, BELGIUM – October 17, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows: Oxurion…
Actusnews Wire
17/10/2025

RAMSAY SANTE : annual results at the end of June 2025

PRESS RELEASE Paris, 17 thOctober 2025 Annual results at the end of June 2025 Revenue growth of 4.7% and Group EBITDA up 1.7% despite reduction in public funding; secured long term financing frameworkActivity growth and cost control mitigate low French tariffs Group revenue increased by 4.7% to €5.2bn supported by activity volume growth and former Cosem primary care centres acquired in June 2024. Revenue growth of 2.7% on a like-for-like basis...
Nasdaq GlobeNewswire
17/10/2025

Zealand Pharma major shareholder announcement: Van Herk Investments B.V.

Company announcement – No. 22 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V.Copenhagen, Denmark, October 17, 2025 –Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports receipt on 16 October 2025 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder:As of 15 October...
Nasdaq GlobeNewswire
17/10/2025
Altri  Comunicati